|
1
|
Chaabane C, Otsuka F, Virmani R and
Bochaton-Piallat ML: Biological responses in stented arteries.
Cardiovasc Res. 99:353–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sprague AH and Khalil RA: Inflammatory
cytokines in vascular dysfunction and vascular disease. Biochem
Pharmacol. 78:539–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rabbani GH, Butler T, Knight J, Sanyal SC
and Alam K: Randomized controlled trial of berberine sulfate
therapy for diarrhea due to enterotoxigenic Escherichia coli and
Vibrio cholerae. J Infect Dis. 155:979–984. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saha P, Bhattacharjee S, Sarkar A, Manna
A, Majumder S and Chatterjee M: Berberine chloride mediates its
anti-leishmanial activity via differential regulation of the
mitogen activated protein kinase pathway in macrophages. PLoS One.
6:e184672011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu HH, Kim KJ, Cha JD, Kim HK, Lee YE,
Choi NY and You YO: Antimicrobial activity of berberine alone and
in combination with ampicillin or oxacillin against
methicillin-resistant Staphylococcus aureus. J Med Food. 8:454–461.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Choo BK and Roh SS: Berberine protects
against esophageal mucosal damage in reflux esophagitis by
suppressing proinflam-matory cytokines. Exp Ther Med. 6:663–670.
2013.PubMed/NCBI
|
|
7
|
Kuo CL, Chi CW and Liu TY: The
anti-inflammatory potential of berberine in vitro and in vivo.
Cancer Lett. 203:127–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahata S, Bharti AC, Shukla S, Tyagi A,
Husain SA and Das BC: Berberine modulates AP-1 activity to suppress
HPV transcription and downstream signaling to induce growth arrest
and apoptosis in cervical cancer cells. Mol Cancer. 10:392011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Katiyar SK, Meeran SM, Katiyar N and
Akhtar S: p53 cooperates berberine-induced growth inhibition and
apoptosis of non-small cell human lung cancer cells in vitro and
tumor xenograft growth in vivo. Mol Carcinog. 48:24–37. 2009.
View Article : Google Scholar
|
|
10
|
Leng SH, Lu FE and Xu LJ: Therapeutic
effects of berberine in impaired glucose tolerance rats and its
influence on insulin secretion. Acta Pharmacol Sin. 25:496–502.
2004.PubMed/NCBI
|
|
11
|
Yin J, Hu R, Chen M, Tang J, Li F, Yang Y
and Chen J: Effects of berberine on glucose metabolism in vitro.
Metabolism. 51:1439–1443. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong Y, Hui SS, Chan BT and Hou J: Effect
of berberine on catecholamine levels in rats with experimental
cardiac hypertrophy. Life Sci. 72:2499–2507. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zeng XH, Zeng XJ and Li YY: Efficacy and
safety of berberine for congestive heart failure secondary to
ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol.
92:173–176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang KW, Ting CT, Yin SC, Chen YT, Lin
SJ, Liao JK and Hsu SL: Berberine suppresses MEK/ERK-dependent
Egr-1 signaling pathway and inhibits vascular smooth muscle cell
regrowth after in vitro mechanical injury. Biochem Pharmacol.
71:806–817. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee S, Lim HJ, Park HY, Lee KS, Park JH
and Jang Y: Berberine inhibits rat vascular smooth muscle cell
proliferation and migration in vitro and improves neointima
formation after balloon injury in vivo. Berberine improves
neointima formation in a rat model. Atherosclerosis. 186:29–37.
2006. View Article : Google Scholar
|
|
16
|
Meng S, Wang LS, Huang ZQ, Zhou Q, Sun YG,
Cao JT, Li YG and Wang CQ: Berberine ameliorates inflammation in
patients with acute coronary syndrome following percutaneous
coronary intervention. Clin Exp Pharmacol Physiol. 39:406–411.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carbone F and Montecucco F: Inflammation
in arterial diseases. IUBMB Life. 67:18–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Korcum AF, Sanlioglu S, Aksu G, Tuncel N
and Erin N: Radiotherapy-induced decreases in substance P levels
may potentiate melanoma growth. Mol Med Rep. 2:319–326.
2009.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Liu SJ, Yin CX, Ding MC, Xia SY, Shen QM
and Wu JD: Berberine suppresses in vitro migration of human aortic
smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1,
and NF-κB. BMB Rep. 47:388–392. 2014. View Article : Google Scholar :
|
|
21
|
Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC
and Ho TY: Berberine suppresses inflammatory agents-induced
interleukin-1beta and tumor necrosis factor-alpha productions via
the inhibition of IkappaB degradation in human lung cells.
Pharmacol Res. 56:193–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi BH, Ahn IS, Kim YH, Park JW, Lee SY,
Hyun CK and Do MS: Berberine reduces the expression of adipogenic
enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol
Med. 38:599–605. 2006. View Article : Google Scholar
|
|
23
|
Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY,
Shin HJ, Kim WS and Kim JB: Berberine suppresses proinflammatory
responses through AMPK activation in macrophages. Am J Physiol
Endocrinol Metab. 296:E955–E964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Charo IF and Taubman MB: Chemokines in the
pathogenesis of vascular disease. Circ Res. 95:858–866. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaneko H, Anzai T, Morisawa M, Kohno T,
Nagai T, Anzai A, Takahashi T, Shimoda M, Sasaki A, Maekawa Y, et
al: Resveratrol prevents the development of abdominal aortic
aneurysm through attenuation of inflammation, oxidative stress, and
neovascularization. Atherosclerosis. 217:350–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Melgarejo E, Medina MA, Sánchez-Jiménez F
and Urdiales JL: Monocyte chemoattractant protein-1: A key mediator
in inflammatory processes. Int J Biochem Cell Biol. 41:998–1001.
2009. View Article : Google Scholar
|
|
27
|
Egashira K: Molecular mechanisms mediating
inflammation in vascular disease: Special reference to monocyte
chemoattractant protein-1. Hypertension. 41:834–841. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
De Martin R, Hoeth M, Hofer-Warbinek R and
Schmid JA: The transcription factor NF-kappaB and the regulation of
vascular cell function. Aterioscler Thromb Vasc Biol. 20:E83–E88.
2000. View Article : Google Scholar
|
|
29
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tham DM, Martin-McNulty B, Wang YX, Wilson
DW, Vergona R, Sullivan ME, Dole W and Rutledge JC: Angiotensin II
is associated with activation of NF-kappaB-mediated genes and
downregulation of PPARs. Physiol Genomics. 11:21–30. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brasier AR: The nuclear
factor-kappaB-interleukin-6 signalling pathway mediating vascular
inflammation. Cardiovasc Res. 86:211–218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aljada A, Ghanim H, Saadeh R and Dandona
P: Insulin inhibits NFkappaB and MCP-1 expression in human aortic
endothelial cells. J Clin Endocrinol Metab. 86:450–453.
2001.PubMed/NCBI
|
|
33
|
Towler MC and Hardie DG: AMP-activated
protein kinase in metabolic control and insulin signaling. Circ
Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fisslthaler B and Fleming I: Activation
and signaling by the AMP-activated protein kinase in endothelial
cells. Circ Res. 105:114–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cacicedo JM, Yagihashi N, Keaney JF Jr,
Ruderman NB and Ido Y: AMPK inhibits fatty acid-induced increases
in NF-kappaB transactivation in cultured human umbilical vein
endothelial cells. Biochem Biophys Res Commun. 324:1204–1209. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Okayasu T, Tomizawa A, Suzuki K, Manaka K
and Hattori Y: PPARalpha activators upregulate eNOS activity and
inhibit cytokine-induced NF-kappaB activation through AMP-activated
protein kinase activation. Life Sci. 82:884–891. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hattori Y, Nakano Y, Hattori S, Tomizawa
A, Inukai K and Kasai K: High molecular weight adiponectin
activates AMPK and suppresses cytokine-induced NF-kappaB activation
in vascular endothelial cells. FEBS Lett. 582:1719–1724. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hattori Y, Suzuki K, Hattori S and Kasai
K: Metformin inhibits cytokine-induced nuclear factor kappaB
activation via AMP-activated protein kinase activation in vascular
endothelial cells. Hypertension. 47:1183–1188. 2006. View Article : Google Scholar : PubMed/NCBI
|
